Cowen Reiterates Esperion Therapeutics (ESPR) at Outperform, CLEAR Outcomes Study Results Could be an Inflection Point for Sales
Tweet Send to a Friend
Cowen analyst Joseph Thome reiterated an Outperform rating and $15.00 price target on Esperion Therapeutics (NASDAQ: ESPR), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
